Biontech and matinas biopharma announce exclusive research collaboration to evaluate novel delivery technology for mrna-based vaccines

Mainz, germany and bedminster, new jersey (usa), april 11, 2022 – biontech se  (nasdaq: bntx, “biontech”) and matinas biopharma (nyse amer: mtnb, “matinas”), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (lnc) platform technology, announced today that they have entered into an exclusive research collaboration to evaluate the combination of mrna formats and matinas' proprietary lnc platform technology. the parties will closely collaborate on formulation, optimization, and in vitro testing.
BNTX Ratings Summary
BNTX Quant Ranking